Targeting IDH in Acute Myeloid Leukemia
This video examines the targeting of IDH1/IDH2 mutations in patients with relapsed or refractory acute myeloid leukemia.
In this video, Courtney D. DiNardo, MD, of MD Anderson Cancer Center in Houston, discusses targeting IDH1/IDH2 mutations in patients with relapsed or refractory acute myeloid leukemia (AML).
IDH mutations occur in roughly 20% of AML patients and recent novel therapies have proven to be effective in this setting. A phase I trial on the novel IDH2-inhibitor enasidenib in relapsed/refractory AML was presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
DiNardo, who has been involved in many of the AML studies using IDH inhibitors, gave a presentation on this topic during an education session at the meeting.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
